Two Sigma Advisers
TERN

Two Sigma Advisers’s Terns Pharmaceuticals TERN Stock Holding History

Two Sigma Advisers’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-316,836
Closed -$1.18M – 2631
2025
Q2 		$1.18M Buy
316,836
+207,236
+189% +$647K ﹤0.01% 1361
2025
Q1 		$302K Buy
+109,600
New +$448K ﹤0.01% 1989
2024
Q4 		– Sell
-32,600
Closed -$272K – 2530
2024
Q3 		$272K Buy
32,600
+4,300
+15% +$35.4K ﹤0.01% 1953
2024
Q2 		$193K Buy
+28,300
New +$171K ﹤0.01% 2226

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Two Sigma Advisers's TERN Position: Q3 2025 in Review

Two Sigma Advisers sold out of Terns Pharmaceuticals (TERN) in Q3 2025, closing a stake of 316,836 shares — an estimated $1.18M sold.

Two Sigma Advisers first reported a position in TERN in Q2 2024 and held it in 4 quarters. The position peaked at $1.18M in Q2 2025. 141 funds tracked by Wall St. Rank hold TERN as of Q3 2025.

  • Two Sigma Advisers reported no remaining Terns Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 316,836 Terns Pharmaceuticals shares in Q3 2025, an estimated $1.18M.
  • Two Sigma Advisers first reported a position in Terns Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Two Sigma Advisers's Terns Pharmaceuticals position peaked at $1.18M in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.